TRCT
EVFM

Tower Research Capital (TRC)’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Tower Research Capital (TRC)’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,846
Closed -$9K – 6988
2022
Q2 		$9K Buy
7,846
+5,012
+177% +$8.27K ﹤0.01% 4637
2022
Q1 		$14K Buy
2,834
+394
+16% +$2.48K ﹤0.01% 3950
2021
Q4 		$14K Buy
+2,440
New +$20.7K ﹤0.01% 4140
2021
Q3 		– Sell
-4,211
Closed -$71K – 6498
2021
Q2 		$71K Buy
4,211
+3,798
+920% +$72K ﹤0.01% 2727
2021
Q1 		$11K Buy
413
+70
+20% +$3.18K ﹤0.01% 4349
2020
Q4 		$12K Sell
343
-3,885
-92% -$140K ﹤0.01% 4235
2020
Q3 		$150K Buy
4,228
+3,247
+331% +$141K ﹤0.01% 2820
2020
Q2 		$42K Buy
981
+858
+698% +$57.8K ﹤0.01% 3194
2020
Q1 		$10K Sell
123
-13
-10% -$1.04K ﹤0.01% 2052
2019
Q4 		$13K Buy
+136
New +$11.5K ﹤0.01% 2221
2016
Q1 		– Sell
-4
Closed -$1K – 5208
2015
Q4 		$1K Sell
4
-25
-86% -$16.5K ﹤0.01% 4229
2015
Q3 		$21K Buy
+29
New +$31.1K ﹤0.01% 1699

Other funds holding EVFM

CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
LTI
Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

Tower Research Capital (TRC)'s EVFM Position: Q3 2022 in Review

Tower Research Capital (TRC) sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2022, closing a stake of 7,846 shares — an estimated $9K sold.

Tower Research Capital (TRC) first reported a position in EVFM in Q3 2015 and held it in 12 quarters. The position peaked at $150K in Q3 2020. 8 funds tracked by Wall St. Rank hold EVFM as of Q3 2022.

  • Tower Research Capital (TRC) reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 7,846 Evofem Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $9K.
  • Tower Research Capital (TRC) first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2015 and held it in 12 quarters.
  • Tower Research Capital (TRC)'s Evofem Biosciences, Inc. Common Stock position peaked at $150K in Q3 2020.
  • 8 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2022, filed 10 Nov 2022.